Encapsulation of florfenicol by in situ crystallization into novel alginate-Eudragit RS® blended matrix for pH modulated release

Effects of short-term florfenicol exposure on the gene expression pattern, midgut microbiota, and metabolome in the lepidopteran model silkworm (Bombyx mori)

Florfenicol (FF), an alternative veterinary antibiotic for chloramphenicol, has been widely utilized in livestock breeding to prevent and treat bacterial diseases. However, the toxicological effects of FF have yet to be fully disclosed. The domesticated silkworm (Bombyx mori), a lepidopteran model, was selected to assess the toxicological effects of FF dietary exposure with multi-omics. The findings showed that high-dose (250 μg/L) FF exposure increased the whole cocoon weight. High-dose FF exposure affected the species richness and community diversity of the microbiota in the silkworm midgut. Biochemical processes and innate immunity were impacted by FF exposure. The KEGG pathways impacted by the midgut microbiota and their metabolites were compared, and several pathways were found to be related to the two ecosystems. In addition, the innate immunity and lipid metabolism pathways were impacted, and some of the differentially expressed genes were enriched in these pathways. These related pathways may involve crosstalk between the midgut microbiota shift, midgut biological functions, and global gene expression. Therefore, our study also advances the application of the silkworm larval model in assessing antibiotic metabolic toxicity and provides novel insights into the potential risks of FF.

Florfenicol sustained-release granules: an in vitro-in vivo correlation study in pigs

The objective of this study was to synthesize and characterize pharmaceutical characteristics of florfenicol sustained-release granules (FSRGs) in vitro and in vivo. FSRGs were synthesized using monostearate, polyethylene glycol 4000 and starch. In vitro dissolution profiles were studied using the rotating basket method in pH 1.2 HCl solution and pH 4.3 acetate buffer. Twenty-four male healthy Landrace×Yorkshire pigs were equally divided into three groups and administered a 20 mg/kg i.v bolus of florfenicol solution and dosed orally with FSRGs in the fasting and fed states. The Higuchi model was the best fit for the drug release profile in pH 1.2 and pH 4.3 media, and the mechanism of drug dissolution was governed by both diffusion and dissolution. We established a level A in vitro - in vivo correlation for FSRGs and the in vivo profile of the FSRGs can be estimated by the in vitro drug release.

Pharmaceutical characterization and pharmacokinetics of florfenicol-loaded alginate dried beads in rabbits

The pharmacokinetic variables of a new formulation of florfenicol included in dried bean of alginate (FADBs), its acceptance as in food medication, and its relationship with theoretical minimum inhibitory concentration (MIC) values of the main pathogens in rabbits, are presented. FADBs sought to mask the unpleasant taste of florfenicol while enhancing sustained absorption in a day to facilitate and optimise its dosage in this species. The entrapment efficiency was determined to be 94-98% and 73.56±3.26% of drug loading. No reduction in food consumption was detected, nor selectivity when choosing from their usual food. The elimination half-life was 1.23 to 2.4 h slower than the one previously reported in the literature. Possible flip-flop pharmacokinetics is proposed for FADBs in rabbits, thus complying better with the key pharmacokinetics/pharmacodynamics (PK/PD) ratio of t≥MIC. Also, if a MIC2.0 μg/mL is taken as the cut-off point for florfenicol in rabbits, then ad libitum intake of FADBs in their standard diet is sufficient to maintain plasma concentrations of florfenicol above this level during the whole dosing interval of 24 h. Additionally, FADBs are a low-cost and attractive drug delivery system for the oral controlled release of florfenicol in rabbits.

Emulsion, hydrogel and emulgel systems and novel applications in cannabinoid delivery: a review

Emulsions, hydrogels and emulgels have attracted a high interest as tools for the delivery of poorly soluble hydrophobic nutraceuticals by enhancing their stability and bioavailability. This review provides an overview of these delivery systems, their unique qualities and their interactions with the human gastrointestinal system. The modulation of the various delivery systems to enhance the bioavailability and modify the release profile of bioactive encapsulates is highlighted. The application of the delivery systems in the delivery of cannabinoids is also discussed. With the recent increase of cannabis legalization across North America, there is much interest in developing cannabis edibles which can provide a consistent dose of cannabinoids per portion with a rapid time of onset. Indeed, the long time of onset of psychoactive effects and varied metabolic responses to these products result in a high risk of severe intoxication due to overconsumption. Sophisticated emulsion or hydrogel-based delivery systems are one potential tool to achieve this goal. To date, there is a lack of evidence linking specific classes of delivery systems with their pharmacokinetic profiles in humans. More research is needed to directly compare different classes of delivery systems for the gastrointestinal delivery of cannabinoids.

In situ Formed Implants, Based on PLGA and Eudragit Blends, for Novel Florfenicol Controlled Release Formulations

Drug controlled release technologies (DCRTs) represent an opportunity for designing new therapies. Main objectives are dose number optimization and secondary effects reduction to improve the level of patient/client acceptance. The present work studies DCRTs based in blended polymeric implants for single dose and long-term therapies of florfenicol (FF), a broad spectrum antibiotic. Polymers used were PLGA and Eudragit E100/S100 types. Eudragit/PLGA and FF/PLGA ratios were the main studied factors in terms of encapsulation efficiencies (EEs) and drug release profiles. In addition, morphological and physicochemical characterization were carried out. EEs were of 50-100% depending on formulation composition, and the FF releasing rate was increased or diminished when E100 or S100 were added, respectively. PLGA hydrolytic cleavage products possibly affect Eudragit solubility and matrix stability. Different mathematical models were used for better understanding and simulating release processes. Implants maintained the antimicrobial activity against Pseudomonas aeruginosa up to 12 days on agar plates. The developed DCRTs represents a suitable alternative for florfenicol long-term therapies.

Thermodynamic and Structural Powder Diffraction Studies of the Polymorphism of Florfenicol

Florfenicol is an antimicrobial drug used in veterinary medicine and aquaculture. Two polymorphic forms called A and B have been reported in literature, but the relation between these two forms are unknown. In order to get a better understanding of the behavior of solid florfenicol and the possible evolution from a metastable form to a stable one, an accurate thermodynamic study has been carried out by calorimetric measurements. For this purpose, temperatures and enthalpies of transition and of fusion of the stable and metastable forms have been measured by DSC. TGA has been used in view to detect the eventual existence of solvates which does not occur. In view to confirm the kind of transition, c_p measurements of the two forms have been performed with a C80 calorimeter. With these c_p values, it has been possible to determine the function of the variation of enthalpies as a function of temperature, ΔH = f (T). A study of the kinetic of transformation has been realized and is presented as well as the patterns of the X-ray powder diffraction from 295 to 426 K. This last approach confirms the crystal structure of form A of florfenicol previously reported in literature.